DrugPatentWatch Database Preview

Odevixibat - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for odevixibat and what is the scope of patent protection?

Odevixibat is the generic ingredient in one branded drug marketed by Albireo and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Odevixibat has one hundred and thirty patent family members in forty-five countries.

Summary for odevixibat

International Patents:	130
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	3
Patent Applications:	118
What excipients (inactive ingredients) are in odevixibat?	odevixibat excipients list
DailyMed Link:	odevixibat at DailyMed

Recent Clinical Trials for odevixibat

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Albireo	Phase 3

See all odevixibat clinical trials

US Patents and Regulatory Information for odevixibat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Albireo	BYLVAY	odevixibat	CAPSULE;ORAL	215498-004	Jul 20, 2021		RX	Yes	Yes			Y	Y
Albireo	BYLVAY	odevixibat	CAPSULE, PELLETS;ORAL	215498-001	Jul 20, 2021		RX	Yes	No
Albireo	BYLVAY	odevixibat	CAPSULE, PELLETS;ORAL	215498-001	Jul 20, 2021		RX	Yes	No			Y	Y
Albireo	BYLVAY	odevixibat	CAPSULE, PELLETS;ORAL	215498-003	Jul 20, 2021		RX	Yes	Yes
Albireo	BYLVAY	odevixibat	CAPSULE;ORAL	215498-004	Jul 20, 2021		RX	Yes	Yes
Albireo	BYLVAY	odevixibat	CAPSULE, PELLETS;ORAL	215498-003	Jul 20, 2021		RX	Yes	Yes
Albireo	BYLVAY	odevixibat	CAPSULE, PELLETS;ORAL	215498-003	Jul 20, 2021		RX	Yes	Yes

International Patents for odevixibat

Country	Patent Number	Estimated Expiration
Serbia	60901
United Kingdom	0209463
Australia	2019290337
Japan	5889321
Israel	279464
Russian Federation	2591188
Canada	2459449